Catalyst Pharmaceuticals (NASDAQ:CPRX) Cut to Buy at StockNews.com

StockNews.com cut shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a strong-buy rating to a buy rating in a research report report published on Saturday.

Several other research firms have also recently commented on CPRX. Bank of America restated a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. HC Wainwright lifted their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday. Truist Financial increased their target price on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, November 11th. Finally, Stephens assumed coverage on shares of Catalyst Pharmaceuticals in a research report on Monday, November 18th. They set an “overweight” rating and a $35.00 price target on the stock. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $32.86.

Catalyst Pharmaceuticals Stock Up 1.3 %

CPRX stock opened at $22.21 on Friday. The stock has a market cap of $2.65 billion, a PE ratio of 18.82, a price-to-earnings-growth ratio of 3.35 and a beta of 0.79. The firm’s 50-day simple moving average is $21.77 and its 200 day simple moving average is $20.02. Catalyst Pharmaceuticals has a fifty-two week low of $13.12 and a fifty-two week high of $24.27.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Gary Ingenito sold 12,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total value of $272,640.00. Following the transaction, the insider now owns 51,391 shares of the company’s stock, valued at approximately $1,167,603.52. This trade represents a 18.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Molly Harper sold 17,500 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total transaction of $385,000.00. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock valued at $1,754,140 in the last quarter. Insiders own 11.00% of the company’s stock.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Large investors have recently made changes to their positions in the company. GAMMA Investing LLC grew its position in Catalyst Pharmaceuticals by 62.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 681 shares in the last quarter. nVerses Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals during the third quarter valued at $50,000. Larson Financial Group LLC raised its position in Catalyst Pharmaceuticals by 27,218.2% during the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 2,994 shares during the period. Meeder Asset Management Inc. purchased a new stake in Catalyst Pharmaceuticals in the 2nd quarter worth about $70,000. Finally, Quantbot Technologies LP acquired a new stake in Catalyst Pharmaceuticals during the 3rd quarter worth about $151,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.